# Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma

> **NCT01157013** · NA · COMPLETED · sponsor: **Hospital Miguel Servet** · enrollment: 40 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **OTHER:** Positron emission tomography with fludeoxyglucose F 18

## Key facts

- **NCT ID:** NCT01157013
- **Lead sponsor:** Hospital Miguel Servet
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-06
- **Final completion:** 2010-06
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2010-07-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01157013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01157013, "Role of Positron Emission Tomography in the Evaluation of Response to Sorafenib in Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01157013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*